Low skeletal muscle mass is predictive of dose-limiting toxicities in head and neck cancer patients undergoing low-dose weekly cisplatin chemoradiotherapy.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
09
2022
accepted:
06
02
2023
entrez:
21
2
2023
pubmed:
22
2
2023
medline:
25
2
2023
Statut:
epublish
Résumé
The dose-limiting effect of CT-assessed low skeletal muscle mass (LSMM) measured at the level of the third cervical vertebra has been found in head and neck cancer patients receiving high-dose cisplatin chemoradiotherapy. The aim of this study was to investigate the predictive factors for dose-limiting toxicities (DLTs) using low-dose weekly chemoradiotherapy. Head and neck cancer patients receiving definite chemoradiotherapy with weekly 40 mg/m2 body surface area (BSA) cisplatin or paclitaxel 45 mg/m2 BSA and carboplatin AUC2 were consecutively included and retrospectively analysed. Skeletal muscle mass was assessed using the muscle surface at the level of the third cervical vertebra in pretherapeutic CT scans. After stratification for LSMM DLT, acute toxicities and feeding status during the treatment were examined. Dose-limiting toxicity was significantly higher in patients with LSMM receiving cisplatin weekly chemoradiotherapy. For paclitaxel/carboplatin, no significance regarding DLT and LSMM could be found. Patients with LSMM had significantly more dysphagia before treatment, although feeding tube placement before treatment was equal in patients with and without LSMM. LSMM is a predictive factor for DLT in head and neck patients treated with low-dose weekly chemoradiotherapy with cisplatin. For paclitaxel/carboplatin, further research must be carried out.
Sections du résumé
BACKGROUND
The dose-limiting effect of CT-assessed low skeletal muscle mass (LSMM) measured at the level of the third cervical vertebra has been found in head and neck cancer patients receiving high-dose cisplatin chemoradiotherapy. The aim of this study was to investigate the predictive factors for dose-limiting toxicities (DLTs) using low-dose weekly chemoradiotherapy.
MATERIALS AND METHODS
Head and neck cancer patients receiving definite chemoradiotherapy with weekly 40 mg/m2 body surface area (BSA) cisplatin or paclitaxel 45 mg/m2 BSA and carboplatin AUC2 were consecutively included and retrospectively analysed. Skeletal muscle mass was assessed using the muscle surface at the level of the third cervical vertebra in pretherapeutic CT scans. After stratification for LSMM DLT, acute toxicities and feeding status during the treatment were examined.
RESULTS
Dose-limiting toxicity was significantly higher in patients with LSMM receiving cisplatin weekly chemoradiotherapy. For paclitaxel/carboplatin, no significance regarding DLT and LSMM could be found. Patients with LSMM had significantly more dysphagia before treatment, although feeding tube placement before treatment was equal in patients with and without LSMM.
CONCLUSIONS
LSMM is a predictive factor for DLT in head and neck patients treated with low-dose weekly chemoradiotherapy with cisplatin. For paclitaxel/carboplatin, further research must be carried out.
Identifiants
pubmed: 36802403
doi: 10.1371/journal.pone.0282015
pii: PONE-D-22-24881
pmc: PMC9942991
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0282015Informations de copyright
Copyright: © 2023 Becker et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
ORL J Otorhinolaryngol Relat Spec. 2018;80(1):1-9
pubmed: 29393251
Eur Arch Otorhinolaryngol. 2019 Apr;276(4):1175-1182
pubmed: 30689037
Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):868-883
pubmed: 28602414
JAMA Oncol. 2016 Jun 01;2(6):782-9
pubmed: 26891703
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
Eur Arch Otorhinolaryngol. 2019 May;276(5):1475-1486
pubmed: 30830300
Eur Radiol. 2021 Jun;31(6):4053-4062
pubmed: 33219847
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
J Clin Med. 2020 Nov 23;9(11):
pubmed: 33238530
Cancers (Basel). 2021 Feb 11;13(4):
pubmed: 33670339
Cancer Chemother Pharmacol. 2018 Jul;82(1):1-29
pubmed: 29876640
Eur Arch Otorhinolaryngol. 2017 Oct;274(10):3757-3765
pubmed: 28755023
Head Neck. 2022 Jan;44(1):189-200
pubmed: 34713519
Radiat Oncol. 2019 Feb 11;14(1):32
pubmed: 30744643
In Vivo. 2021 Sep-Oct;35(5):2801-2808
pubmed: 34410971
Oncologist. 2017 Sep;22(9):1056-1066
pubmed: 28533474
World J Gastroenterol. 2011 Feb 28;17(8):1004-8
pubmed: 21448351
Radiother Oncol. 2020 Jun;147:103-110
pubmed: 32251949
Oral Oncol. 2016 Nov;62:28-33
pubmed: 27865369
Lancet. 2019 Jun 29;393(10191):2636-2646
pubmed: 31171417
Radiat Oncol J. 2020 Jun;38(2):138-147
pubmed: 33012157
Am J Clin Nutr. 2004 Nov;80(5):1215-21
pubmed: 15531668
J Clin Oncol. 2022 Jun 20;40(18):1980-1990
pubmed: 35230884
PLoS One. 2021 Oct 29;16(10):e0259288
pubmed: 34714876
J Clin Gastroenterol. 2018 Oct;52(9):753-764
pubmed: 29924079
J Appl Physiol (1985). 2004 Dec;97(6):2333-8
pubmed: 15310748
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1333-8
pubmed: 19540060
Head Neck. 2016 Apr;38 Suppl 1:E2151-8
pubmed: 25735803
Oral Oncol. 2021 Dec;123:105617
pubmed: 34749251
J Clin Oncol. 1989 Nov;7(11):1748-56
pubmed: 2681557
Clin Geriatr Med. 2017 Feb;33(1):17-26
pubmed: 27886695
Eur Arch Otorhinolaryngol. 2022 Jul;279(7):3685-3694
pubmed: 35038029
Head Neck. 2019 May;41(5):1490-1498
pubmed: 30835900
Eur J Cancer. 2016 Apr;57:58-67
pubmed: 26882087
Clin Nutr. 2021 Oct;40(10):5298-5310
pubmed: 34536638
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
Oral Oncol. 2017 Aug;71:26-33
pubmed: 28688687